Cipla Gets A Regulatory Nod For Coronavirus Drug

June 22, 2020 12:05
Cipla Gets A Regulatory Nod For Coronavirus Drug

(Image source from:

Cipla Gets A Regulatory Nod For Coronavirus Drug:- The Indian pharmaceutical companies stepped out with a series of announcements that are made over the weekend to treat the coronavirus patients. After Glenmark Pharmaceuticals and Hetero Gropu, Cipla is said to have received approval from the Drug Controller General of India (DGCI) to manufacture and market the generic version of experimental treatment Remdesivir. The drug is named Cipremi. Gilead Sciences signed a non-exclusive licensing pacts with five generic drug makers based in India and Pakistan.

Cipremi is also given as an injection and Cipla revealed that they would produce this in association with various pharmaceutical firms in India. Cipla revealed that all those who are struggling to breathe and are on a ventilator can be treated with Cipremi. The price would range in between Rs 5000 and 6000. A patient would need seven bottles of Cipremi and it would cost close to Rs 40,000 to treat patient suffering from coronavirus. India is now having over 4.25 lakh cases of coronavirus and 445 people passed away in the country yesterday. The total number of deaths registered in the country due to coronavirus is said to be 13,699.

(Video Source: Mahaa News)

If you enjoyed this Post, Sign up for Newsletter

(And get daily dose of political, entertainment news straight to your inbox)

Rate This Article
(0 votes)
Tagged Under :
Cipla  Coronavirus  Cipremi